Data / Drug companies / Methenamine hippurate
Methenamine hippurate: 12 companies and 12 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Methenamine hippurate is listed in the FDA National Drug Code Directory by 12 companies, with 12 products in commercial distribution. 10 of the products (83.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, and the newest product started marketing on July 27, 2026.
The request: Get every company that lists methenamine hippurate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 12
- Products
- 12
- Generic (ANDA) products
- 10 (83.3%)
- Application numbers
- 7
- Routes
- Oral
- openFDA record search
- api.fda.gov
Companies that list methenamine hippurate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Alvogen Inc. | 1 | tablet | New drug applications (NDA) | May 3, 2010 |
| American Health Packaging | 1 | tablet | Generic drugs (ANDA) | August 12, 2022 |
| Ani Pharmaceuticals, Inc. | 1 | tablet | New drug applications (NDA) | July 27, 2026 |
| Aurobindo Pharma Limited | 1 | tablet | Generic drugs (ANDA) | July 5, 2016 |
| AvPAK | 1 | tablet | Generic drugs (ANDA) | December 2, 2020 |
| Golden State Medical Supply, Inc. | 1 | tablet | Generic drugs (ANDA) | November 27, 2020 |
| Ingenus Pharmaceuticals, LLC | 1 | tablet | Generic drugs (ANDA) | December 18, 2020 |
| Jubilant Cadista Pharmaceuticals Inc. | 1 | tablet | Generic drugs (ANDA) | January 24, 2023 |
| Micro Labs Limited | 1 | tablet | Generic drugs (ANDA) | August 15, 2019 |
| NorthStar RxLLC | 1 | tablet | Generic drugs (ANDA) | April 1, 2025 |
| Viona Pharmaceuticals Inc | 1 | tablet | Generic drugs (ANDA) | March 12, 2025 |
| Zydus Lifesciences Limited | 1 | tablet | Generic drugs (ANDA) | March 12, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 12 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 10 | 83.3% |
| New drug applications (NDA) | 2 | 16.7% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.